Shilpa Medicare L News

Compliance certificate under Reg 74(5) of SEBI (DP) Regulations 2018

Europe Approval for Tadalafil Orodisperible films

Closure of Trading Window

Eurasia (EAEU) GMP Approval of Shilpa Medicare Ltd, Unit IV , Jadcherla, Telangana and Unit VII Nacharam, Hyderabad, Telangana

Europe GMP Certificate for Shilpa Medicare Limited, Unit VII, Nacharam, Hyderabad from EMA, Austria

USFDA Approval of NDA - Imatinib Oral Solution

Indian Regulatory Authority - SEC approval for conducting Phase III clinical trials for Recombinant Human Albumin (eHA) 20%

Transcript Q2-H1-FY24-25

Shilpa Pharma Lifesciences Limited received CEP from EDQM for API , Nifedipine

Waaree Energies, which recently made a stellar debut at the bourses, reported its first earnings post listing, where the solar PV maker clocked 15% growth in its second quarter net profit at Rs 362 crore.

Shilpa Medicare Limited''s 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM, for API, Octreotide.

Audio Recording of the conference call held on Thursday, 14 November 2024, uploaded on our website.

Pursuant to Regulation 32(6) of SEBI (LODR) Regulation,2015 read with Regulation 41 (4) of SEBI( ICDR)Regulation, 2018, enclosed herewith Monitoring agency report of the quarter ended 30 September 2024

Investor presentation for the quarter ended 30th September, 2024

The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2024

Considered and approved1.The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30September 2024. A copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1.2.Inducted Dr. Anita Bandyopadhyay, Non-Executive Independent Director as a member of Audit Committee.

Shilpa Medicare announces acceptance by USFDA of NDA filled by its CDMO partner Unicycive - for Oxylanthanum Carbonate (OLC)

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q4 & year ended 31 March 2024 Conference Call to be held on Friday, May 24, 2024 at 1:00 PM IST

SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 ,inter alia, to consider and approve Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024

Conclusion of USFDA inspection of Shilpa Medicare Ltd, Unit VI Bengaluru, Karnataka

Shilpa Medicare Limited (SML) ''s CDMO customer receives Fast- Track Designation for its investigational drug candidate

Compliances- Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018

Shares of Shilpa Medicare will be highlighted as its subsidiary, Shilpa Pharma Lifesciences, obtained a certificate of suitability from European regulators for Desmopressin. This API is used in diabetes treatment. The certification marks a milestone for the company. Shilpa Medicare's stock has increased notably in 2024 despite recent declines.

M&M Financial is likely to be in focus as the company said it is expecting a 1% year-on-year decline in the overall disbursement in the second quarter.

Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Desmopressin

Closure of Trading Window

The Exchange has received the revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September 26, 2024 for Ramakant Innani

The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September 24, 2024 for Ramakant Innani & Others

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 26, 2024 for Ramakant Innani & Others

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 24, 2024 for Ramakant Innani & Others

Revised Disclosure under Regulation 31 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Disclosure under Regulation 31 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Voting Results and Scrutinizer Report of 37th AGM

Appointment of Dr. Sridevi Khambhampaty as CEO of Shilpa Biologicals Pvt. Ltd, a Wholly Owned Subsidiary of Shilpa Medicare Limited

Pursuant to Regulation 30 read with Part A of Schedule III of SEBI(LODR) Regulations, submitting the proceedings of the 37th Annual General Meeting of the Company.

Release of Non Disposal Undertaking (NDU) by certain identified promoters of the Company

Shilpa Medicare announces submission of NDA to U.S FDA by unicycive - Its First Regulatory submissions from CDMO partnered projects

USFDA Approval for Bortezomib injection NDA 212782

Shilpa Medicare, held by Madhusudhan Kela and Sunil Singhania, has returned 45% since its QIP allotment four months ago. Singhania's Abakkus Diversified Alpha Fund-2 received 6 lakh shares, while Kela’s Cohesion MK Best Ideas Sub-Trust was allotted 8.79 lakh shares.

Business Responsibility and Sustainability Reporting (BRSR) for the FY 2023-24